Ascelia Pharma AB (publ) (ACE) Q2 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Welcome to Ascelia Pharma Q2 twenty twenty six Report Presentation. For the first part of the conference, participants will be in listen only mode. During the questions and answer session, participants are able to ask questions by dialing pound key Now I will hand the conference over to CEO, Magnus Korfetzen CFO, Anton Hansen and CSO, Andreas Norlin. Please go ahead. Thank you, and welcome everyone to the webcast for Ascelia Pharma's Q2 report for 2027. On this call, we will be making forward looking statements. On today's call, will start with an overview of Ascelia Pharma and recent key events, and then head into our portfolio update with an emphasis on the recent complete response letter for Orbiglans before moving to financials and priorities ahead. After the presentation, we will open up for questions. At Ascelia Pharma, we identify, develop, commercialize novel drugs that address unmet medical needs within rare cancer conditions. We're based in Malmo in Sweden, and we're listed on nastax.com. We have two drugs in our pipeline. OrbiGlance is a diagnostic not diagnostic drug, and we have submitted a new drug application to the FDA to obtain approval in The US. We received a complete response letter in early July, and we'll meet with the FDA on September 9 to find the the path to approval. Oncoral is a patented tablet formulation of ibenzotikin with encouraging results in phase one and potential to treat a range of solid tumors. In April, we raised 20,000,000 Swedish krona in a directed share issue, and in May, we had our annual general meeting as usual. In June, all the cleanse data was presented at the ESCA conference, the major European conference for gastrointestinal and abdominal radiology. At the end of the quarter, we filed a patent application regarding pa...